Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Baxter
Fuji
Novartis
Dow
Citi
Medtronic
Federal Trade Commission
Express Scripts

Generated: August 18, 2017

DrugPatentWatch Database Preview

Novartis Pharms Corp Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?

NOVARTIS PHARMS CORP has sixty-eight approved drugs.

There are one hundred and eighteen US patents protecting NOVARTIS PHARMS CORP drugs and there have been five Paragraph IV challenges on NOVARTIS PHARMS CORP drugs in the past three years.

There are one thousand seven hundred and eighty-eight patent family members on NOVARTIS PHARMS CORP drugs in seventy-two countries.

Summary for Applicant: Novartis Pharms Corp

Patents:118
Tradenames:58
Ingredients:49
NDAs:68
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
FLUORESCITE
fluorescein sodium
INJECTABLE;INTRAVENOUS021980-001Mar 28, 2006APRXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
MEKINIST
trametinib dimethyl sulfoxide
TABLET;ORAL204114-003May 29, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
INJECTABLE;INJECTION020007-001Jan 4, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
ZOFRAN PRESERVATIVE FREE
ondansetron hydrochloride
INJECTABLE;INJECTION020007-003Dec 10, 1993► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-002Dec 31, 1992► Subscribe► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-002Jan 27, 1999► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-002Oct 11, 2007► Subscribe► Subscribe
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-002Mar 30, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for NOVARTIS PHARMS CORP drugs

Drugname Dosage Strength Tradename Submissiondate
travoprost
Ophthalmic Solution0.003%
IZBA
12/30/2015
nepafenac
Ophthalmic Suspension0.3%
ILEVRO
12/21/2015
deferasirox
Tablets180 mg
JADENU
10/23/2015
deferasirox
Tablets90 mg and 360 mg
JADENU
10/19/2015
olopatadine hydrochloride
Ophthalmic Solution0.7%
PAZEO
9/10/2015
difluprednate
Ophthalmic Emulsion0.05%
DUREZOL
5/1/2014
eltrombopag olamine
Tablets12.5 mg and 25 mg
PROMACTA
2/4/2014
eltrombopag olamine
Tablets50 mg and 75 mg
PROMACTA
1/7/2014
ciprofloxacin and dexamethasone
Otic Suspension0.3%/0.1%
CIPRODEX
7/31/2012
moxifloxacin hydrochloride
Ophthalmic Solution10.5%
MOXEZA
2/29/2012
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
lapatinib ditosylate
Tablets250 mg
TYKERB
3/14/2011
olopatadine hydrochloride
Nasal Spray0.665 mg/ Spray
PATANASE
6/29/2009
travoprost (preserved)
Ophthalmic Solution0.00%
TRAVATAN Z
2/19/2009
olopatadine hydrochloride
Ophthalmic Solution0.20%
PATADAY
9/8/2008
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007
olopatadine hydrochloride
Ophthalmic Solution0.10%
PATANOL
7/17/2006
moxifloxacin hydrochloride
Ophthalmic0.50%
VIGAMOX
12/22/2005
ondansetron hydrochloride
Oral Solution4 mg/5 mL
ZOFRAN
12/20/2004

Non-Orange Book Patents for Novartis Pharms Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,479Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity► Subscribe
6,583,124 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
7,709,012Ophthalmic compositions containing a synergistic combination of two polymers► Subscribe
7,589,2005-Fluoro-4N-phenyl-4-pyrimidineamine compounds► Subscribe
8,952,018Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Corp Drugs

Country Document Number Estimated Expiration
Hong Kong1156625► Subscribe
Israel127212► Subscribe
Australia2011326620► Subscribe
Norway2016014► Subscribe
European Patent Office2638030► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140036 00120Estonia► SubscribePRODUCT NAME: TRAMETINIIB;REG NO/DATE: EU/1/14/931 02.07.2014
00683Netherlands► SubscribePRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
C/GB03/004United Kingdom► SubscribePRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
2015 00047Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Deloitte
McKinsey
Boehringer Ingelheim
Fuji
Baxter
Novartis
Cerilliant
Argus Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot